| Autor: |
Ogawa T; Department of Urology, Kobe University, School of Medicine, Japan., Gotoh A, Takenaka A, Hara I, Gohji K, Arakawa S, Matsumoto O, Kamidono S |
| Jazyk: |
angličtina |
| Zdroj: |
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 1992; Vol. 30 Suppl, pp. S66-71. |
| DOI: |
10.1007/BF00686946 |
| Abstrakt: |
We have treated advanced transitional-cell carcinoma of the urothelial tract with methotrexate, vinblastine, Adriamycin, and cisplatin (M-VAC) chemotherapy since July of 1985. We analyzed the effect of that chemotherapy in 26 patients with advanced urothelial cancer who were treated in our hospital and followed up. They were divided into two groups. Group 1 consisted of 15 patients with distant metastases. In all, 11 of them received M-VAC as adjuvant chemotherapy for metastatic lesions after surgical removal of the primary lesion, and the remaining 4 patients were not operable since they had very advanced-stage tumors; they received only M-VAC chemotherapy. Group 2 contained 11 patients who received M-VAC neo-adjuvant chemotherapy. In group 1, the overall response rate was 57.1% and the mean duration of response was 12.6 months. In the 11 patients who had received M-VAC as adjuvant therapy after surgical removal of the primary tumor, the mean duration of response was 14.1 months. After M-VAC chemotherapy, six patients underwent surgical resection of metastatic lesions and restaging was done pathologically in these cases. The clinical response coincided with the pathological response in all six cases. In group 2, 5 of 11 patients experienced histological downstaging of the resected bladder. M-VAC chemotherapy combined with surgical resection of residual tumors has proved to be an effective option against advanced urothelial cancer. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink